Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States.
The last earnings update was 67 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Palatin Technologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Palatin Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
Palatin Technologies's earnings are expected to grow significantly at over 20% yearly.
Palatin Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Palatin Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Palatin Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Palatin Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Palatin Technologies has no long term commitments.
This treemap shows a more detailed breakdown of
Palatin Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 10.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief Technical Officer and Executive Vice President of Palatin Technologies Inc. From June 1993 to June 1996, he served as Vice President of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm and of Castle Group Ltd., a medical venture capital firm. At Paramount Capital Investments and at Castle Group, Dr. Spana was responsible for discovering, evaluating and commercializing biotechnologies. Through his work at Paramount Capital Investments and Castle Group, he co-founded and acquired several private biotechnology firms. He served as AVAX Technologies, Inc.'s interim President from August 1995 to June 15, 1996. He served as an Chief Technology Officer and Executive Vice President of Rhomed Incorporated. From July 1991 to June 1993, he served as a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana’s qualifications for our board include his leadership experience, business judgment and industry experience. As a senior executive of Palatin for over nineteen years, he provides in-depth knowledge of Palatin Technologies, Inc. company's drug products under development and the competitive and corporate partnering landscape. Dr. Spana has been a Director of Palatin Technologies Inc. since June 1996 and Curalogic A/S since 2005. He has been a Director of RhoMed Incorporated, a wholly-owned subsidiary of Palatin Technologies Inc. since July 1995. Dr. Spana served as a Director of AVAX Technologies, Inc since September 1995. Dr. Spana received his Ph.D. in Molecular Biology from The Johns Hopkins University and his B.S. in Biochemistry from Rutgers University.
Carl's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Carl's remuneration is higher than average for companies of similar size in Germany.
John K. Prendergast
Co-Founder & Non-Executive Chairman
Vice President of Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Palatin Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.